Nebraska Multistate Pharmacy Jurisprudence Examination (MPJE) Practice Exam (Sample)

Study Guide

Everything you need from our exam experts!

Questions

1. Who is responsible for submitting the Pharmacy Quality Assurance Report?

A. Pharmacy Owner

B. Pharmacist-in-Charge (PIC)

C. Department of Health and Human Services

D. Pharmacy Technician

2. What type of knowledge is required for a professional to report unprofessional conduct from another professional?

A. Hearsay

B. Second-hand knowledge

C. First-hand knowledge

D. Assumptions

3. What is the maximum allowed pharmacy technician to pharmacist ratio in Nebraska?

A. 4 technicians to 1 pharmacist

B. 2 technicians to 1 pharmacist

C. 3 technicians to 1 pharmacist

D. 2 technicians and 1 intern to 1 pharmacist

4. What schedule is oxandrolone (Oxandrin) classified under?

A. C1

B. C2

C. C3

D. C4

5. What educational qualification is necessary for a pharmacy technician?

A. Must have a college degree

B. Must have a high school diploma

C. Must have completed a pharmacy technician program

D. No formal education is required

6. Which of the following is not a focus of Phase 3 clinical testing?

A. Drug safety

B. Comparison with a control group

C. Evaluating drug effectiveness

D. Examining drug interactions

7. Which act encouraged manufacturers to research new uses for drugs and submit Supplemental New Drug Applications (SNDAs)?

A. FDA Modernization Act 1997

B. Kefauver-Harris Amendment 1962

C. Durham-Humphrey Amendment 1951

D. Orphan Drug Act 1983

8. How soon after the e-kit is opened should the pharmacy be notified?

A. Within 12 hours

B. Within 24 hours

C. Within 48 hours

D. Within 72 hours

9. For how long should records of inventory counts be maintained?

A. 2 years

B. 3 years

C. 5 years

D. 7 years

10. When can a pharmacist collect a returned drug?

A. Only if the patient requests it

B. If the drug is intact and unopened

C. When it is being returned for disposal

D. All of the above

Answers

1. B
2. C
3. B
4. C
5. B
6. D
7. A
8. B
9. C
10. C

Explanations

1. Who is responsible for submitting the Pharmacy Quality Assurance Report?

A. Pharmacy Owner

B. Pharmacist-in-Charge (PIC)

C. Department of Health and Human Services

D. Pharmacy Technician

The Pharmacist-in-Charge (PIC) holds the responsibility for submitting the Pharmacy Quality Assurance Report. This role is significant as the PIC is designated to oversee the operations of the pharmacy, ensuring compliance with all applicable laws and regulations. The PIC not only manages the pharmacy's day-to-day activities but also plays a crucial role in maintaining the quality and safety of pharmaceutical services provided to patients. By being accountable for the submission of this report, the PIC ensures that the pharmacy adheres to standards that protect patient safety and the integrity of pharmaceutical care. This includes systematic monitoring and evaluation of pharmacy practices, medication storage, and dispensing processes, as well as any adverse events that may occur within the pharmacy context. The other options, such as the Pharmacy Owner, Department of Health and Human Services, and Pharmacy Technician, while they hold important roles within a pharmacy's operations, do not carry the direct responsibility of submitting the Pharmacy Quality Assurance Report as dictated by regulations. The PIC's expertise and oversight capacity make them the appropriate individual for this task, central to maintaining the pharmacy's operational standards.

2. What type of knowledge is required for a professional to report unprofessional conduct from another professional?

A. Hearsay

B. Second-hand knowledge

C. First-hand knowledge

D. Assumptions

First-hand knowledge is essential when reporting unprofessional conduct from another professional because it ensures that the information being conveyed is accurate, reliable, and based on direct observation or experience. First-hand knowledge involves direct experience with the events or actions that may constitute unprofessional conduct, which enhances the credibility of the report being made. This type of knowledge is crucial because it minimizes the risk of misinformation that can arise from hearsay, which is often unverified and may lead to misunderstandings or misinterpretations. In regulatory and legal contexts, authorities generally require reports to be based on first-hand accounts to ensure that appropriate actions can be taken based on factual evidence rather than assumptions or secondary information. Relying on first-hand knowledge allows the reporter to provide clear details and context about the observed behavior, making it easier for regulatory bodies to investigate and address the claim effectively.

3. What is the maximum allowed pharmacy technician to pharmacist ratio in Nebraska?

A. 4 technicians to 1 pharmacist

B. 2 technicians to 1 pharmacist

C. 3 technicians to 1 pharmacist

D. 2 technicians and 1 intern to 1 pharmacist

In Nebraska, the maximum allowed pharmacy technician to pharmacist ratio is set at 2 technicians for every 1 pharmacist. This ratio ensures that pharmacists can adequately oversee their work, providing necessary guidance and ensuring patient safety. It's important that pharmacists maintain oversight of pharmacy activities, which this ratio supports by limiting the number of technicians they can supervise at any given time. The other options either exceed this established ratio or include components not defined in state regulations, potentially leading to confusion about the roles and responsibilities of both pharmacists and technicians in a pharmacy setting. By following this ratio, pharmacies can ensure compliance with state regulations while maintaining high standards of care and supervision.

4. What schedule is oxandrolone (Oxandrin) classified under?

A. C1

B. C2

C. C3

D. C4

Oxandrolone, commonly known by its brand name Oxandrin, is classified as a Schedule III controlled substance under the Controlled Substances Act. This classification is significant because it dictates the regulations surrounding the manufacture, distribution, prescribing, and dispensing of the drug. Schedule III substances are defined as drugs with a potential for abuse less than that of Schedule I and II drugs, and they may lead to moderate or low physical dependence or high psychological dependence. Oxandrolone is used medically, particularly for weight gain and muscle recovery, but it is also known for its performance-enhancing potential, which contributes to its controlled status. Understanding the scheduling system is crucial for pharmacy practice, as it impacts how pharmacy professionals handle, store, and track controlled substances in compliance with regulatory standards.

5. What educational qualification is necessary for a pharmacy technician?

A. Must have a college degree

B. Must have a high school diploma

C. Must have completed a pharmacy technician program

D. No formal education is required

A pharmacy technician is required to have at least a high school diploma as part of the educational qualification needed to practice in many states, including Nebraska. This foundational level of education ensures that the technician possesses basic skills in reading, writing, and mathematics, which are essential for understanding prescriptions and medication dosages, as well as for performing calculations necessary for pharmaceutical care. While some states may require additional certification or completion of a pharmacy technician training program, the minimum educational requirement generally starts with a high school diploma. This requirement helps to maintain a standardized entry-level competency in the workforce, promoting safety and efficacy in pharmacy operations. In summary, possessing a high school diploma allows pharmacy technicians to effectively support pharmacists in their duties while ensuring that they have a solid educational foundation to build upon as they continue their professional development in the pharmacy field.

6. Which of the following is not a focus of Phase 3 clinical testing?

A. Drug safety

B. Comparison with a control group

C. Evaluating drug effectiveness

D. Examining drug interactions

Phase 3 clinical testing serves a critical role in the drug approval process, primarily focusing on evaluating the drug's effectiveness and safety in a larger population. This phase is designed to provide comprehensive data on how the drug performs in comparison to a control group, which may be a placebo or current standard treatment. The results from these tests are crucial for regulatory approval and for understanding the drug's overall benefit-risk profile. While examining drug interactions is an important aspect of pharmacology, it is typically not the primary focus of Phase 3 trials. Instead, detailed assessments regarding drug interactions are often explored during earlier phases or in post-marketing studies, as Phase 3 primarily aims to confirm the drug's efficacy and monitor its safety across a broader demographic before it enters the market. In summary, while drug safety, comparison with a control group, and evaluating drug effectiveness are fundamental elements of Phase 3 clinical testing, examining drug interactions is not at the forefront during this stage, thus making it the correct choice for what is not a primary focus.

7. Which act encouraged manufacturers to research new uses for drugs and submit Supplemental New Drug Applications (SNDAs)?

A. FDA Modernization Act 1997

B. Kefauver-Harris Amendment 1962

C. Durham-Humphrey Amendment 1951

D. Orphan Drug Act 1983

The FDA Modernization Act of 1997 significantly encouraged manufacturers to explore new applications for existing drugs. This act streamlined the regulatory process, allowing for more efficient review of Supplemental New Drug Applications (SNDAs). By reducing barriers and increasing incentives for pharmaceutical companies to conduct research into additional therapeutic uses of their drugs, the act aimed to promote innovation within the industry. Within the context of FDA history, the act also updated various provisions related to drug approval, ensuring that companies could more readily submit applications for new indications or formulations without facing excessive delays. This focus on encouraging manufacturers to research and submit SNDAs was central to the act's goals of enhancing public health by making new therapies available more quickly. The other acts mentioned, while impactful, primarily addressed different aspects of drug regulation, such as safety and efficacy requirements, or the need for prescription labeling. They do not specifically target manufacturers' encouragement to research new applications as the FDA Modernization Act does.

8. How soon after the e-kit is opened should the pharmacy be notified?

A. Within 12 hours

B. Within 24 hours

C. Within 48 hours

D. Within 72 hours

The correct response is that the pharmacy should be notified within 24 hours after the emergency kit (e-kit) is opened. This timeframe is established to ensure that the pharmacy can track the use of medications contained within the e-kit and assess any necessary replenishment of medications. Timely notification is essential for maintaining proper inventory levels, ensuring that the e-kit remains stocked for future emergencies, and complying with regulatory requirements. Furthermore, the 24-hour notification period allows for prompt investigation into the circumstances of the opening and ensures patient safety by confirming that all necessary medications are available for use when needed. By adhering to this guideline, the pharmacy plays a critical role in patient care and safety, as well as regulatory compliance. Other timeframes of 12, 48, or 72 hours would potentially prolong the period before the pharmacy is aware of changes in the e-kit's status, leading to possible shortages or delays in emergency preparedness.

9. For how long should records of inventory counts be maintained?

A. 2 years

B. 3 years

C. 5 years

D. 7 years

The maintenance of inventory count records is crucial for compliance with federal and state regulations governing pharmacy practice. In Nebraska, as well as under federal law, the requirement is to keep records pertaining to controlled substances for a minimum of five years. This includes records like inventory counts, which help ensure accurate tracking and accountability of these substances. Maintaining inventory records for five years aligns with the audit and verification processes needed for compliance with various regulatory bodies. This timeframe allows for sufficient review in case of audits, investigations, or discrepancies that may arise long after the inventory was taken. Thus, the choice indicating a five-year retention period is the correct response in this context, as it fulfills both legal and operational requirements for pharmacies.

10. When can a pharmacist collect a returned drug?

A. Only if the patient requests it

B. If the drug is intact and unopened

C. When it is being returned for disposal

D. All of the above

A pharmacist can collect a returned drug primarily when it is being returned for disposal. This is because returned medications pose safety and legal concerns. If a drug has been dispensed and returned, it cannot generally be put back into inventory for safety reasons, which is critical for both patient health and regulatory compliance. When it comes to accepting returned medications, regulations typically prioritize situations where the drugs are deemed unfit for patient use or need to be disposed of due to expiration or other safety concerns. The option regarding collecting a returned drug only upon patient request does not encompass the full scope of what is permissible in practice, as patient requests might not align with safe disposal practices. Similarly, the notion that a drug can only be returned if it is intact and unopened also does not adequately address the legal framework around drug returns – even unopened drugs may still require specific conditions for return or disposal adhering to regulatory guidelines. Therefore, while a drug's condition may play a role in its acceptability for return, the primary reason a pharmacist would collect a returned drug is specifically tied to its return for proper disposal.